首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1733802

2026 年至 2032 年肾上腺素注射器市场（按产品类型、分销管道、最终用户和地区划分）

Epinephrine Autoinjector Market By Product Type, Distribution Channel, End-User, & Region For 2026-2032

出版日期: 2025年05月13日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

肾上腺素注射器市场评估－2026-2032

由于各种严重过敏反应（例如过敏性休克）的增多，肾上腺素注射器市场需求旺盛；因此，快速注射肾上腺素对于避免潜在的致命后果至关重要。随着过敏在世界日益普遍，医疗保健专业人员和公众越来越意识到在紧急情况下快速获取肾上腺素的必要性。这种认知推动了对即使是医疗经验较少的人也能轻鬆使用的自动注射器的需求，预计到2024年，该市场的销售额将超过28.3亿美元，到2032年，其估值将达到约52.4亿美元。

食物过敏、昆虫毒液过敏和其他过敏原的日益流行，正在显着推动市场成长。这些过敏症可能导致易感族群出现突发性严重反应，需要快速注射肾上腺素来缓解症状并预防过敏性休克。在学校、公共场所等社区环境以及医院等对过敏情况快速反应至关重要的场所，自动注射器至关重要。此外，自动注射器技术的进步使其更加用户友好、便携和安全，对消费者和医疗保健提供者都更具吸引力，推动市场在2026年至2032年间以8.00%的复合年增长率增长。

肾上腺素注射器市场定义/概述

肾上腺素注射器是一种用于治疗严重过敏反应（例如过敏性休克）的紧急医疗设备。它可以快速有效地将肾上腺素（也称为肾上腺素）注入体内，以治疗呼吸困难、喉咙和脸部肿胀、低血压和心率加快等过敏症状。该装置旨在方便非医务人员在需要即时救援时操作。

肾上腺素注射器主要用于需要即时介入以挽救生命的紧急情况。有严重过敏或过敏性休克病史的人通常会获得肾上腺素注射器，并接受如何使用和何时使用的训练。这些设备通常放置在学校、职场和可能存在过敏原的公共场所，作为紧急准备的一部分。快速注射肾上腺素可以显着改善预后，迅速逆转过敏性休克的危险症状，并为急救人员的到达争取关键时间。

随着肾上腺素注射器在控制严重过敏反应（如过敏性休克）方面的有效性和便利性不断提升，其未来前景一片光明。这些装置能够精准注射肾上腺素，逆转可能危及生命的过敏反应，并在几个关键领域中持续取得进展。首先，研究正在不断改进自动注射器的设计和易用性，使其在紧急情况下更容易使用，即使是没有医疗经验的人也能轻鬆使用。

食物过敏的增加会推动肾上腺素注射器市场的发展吗？

全球范围内食物过敏的日益普及推动了肾上腺素注射器产业的发展。例如，美国食物过敏研究与教育组织 (FARE) 报告称，有 3,200 万人患有食物过敏，较前几年显着增加。同样，澳洲国家健康与医学研究委员会 (NHMRC) 报告称，4-6% 的儿童和 1-2% 的成年人患有食物过敏。这些数据表明，食物过敏患者的数量每年都在持续增加。

自动注射器对于控制严重过敏反应至关重要，因为它允许患者使用预填充式注射器快速有效地自行注射肾上腺素，而无需像传统方法那样准备注射器或管瓶以备紧急情况使用。自动注射器的便利性和简单性使其成为全球数百万食物过敏患者的必需品，他们依靠它快速有效地逆转可能致命的过敏反应。

高品牌价格会阻碍肾上腺素注射器市场吗？

像辉瑞Epipen这样的品牌肾上腺素注射器价格高昂，是整个市场面临的一大障碍。这些设备对于治疗严重过敏反应（过敏性休克）至关重要，但其高昂的价格往往意味着许多有需要的人难以负担。这种负担能力问题也影响医疗机构和学校，它们难以确保这些救生设备的充足供应。例如，2021年的一项调查显示，四分之一的芝加哥学校将高昂的处方笺价格列为它们没有肾上腺素注射器的原因。

为了应对这些问题，近年来人们逐渐转向更廉价的学名药。这些学名药疗效相当，但价格更低，旨在使更多人能够更轻鬆地获得肾上腺素注射器。儘管有这种趋势，但只要原厂药的价格限制了这些器械的供应和可负担性，这些器械的市场就仍然未充分开发。努力克服这些成本限制可能会开启新的商机，并使更多人和机构能够获得用于治疗严重过敏症的救命疗法。

The epinephrine autoinjector market is experiencing high demand due to a variety of rise in occurrence of severe allergic reactions such as anaphylaxis; thereby, necessitating the prompt delivery of epinephrine to avoid potentially fatal consequences. With allergies growing more common around the world, healthcare professionals and the general public are more aware of the need of having quick access to epinephrine in an emergency. This knowledge has increased demand for autoinjectors, which are designed for simple, user-friendly administration even by those with little medical experience by enabling the market to surpass a revenue of USD 2.83 Billion valued in 2024 and reach a valuation of around USD 5.24 Billion by 2032.

The rising prevalence of food allergies, insect venom allergies, and other allergens has greatly boosted market growth. These allergies can cause abrupt and severe reactions in susceptible people demanding prompt epinephrine administration to ease symptoms and prevent anaphylactic shock. Autoinjectors are indispensable in both community settings such as schools and public areas, and in hospital facilities where prompt reaction to allergy situations is critical. Furthermore, developments in autoinjector technology have increased device usability, mobility, and safety features making them more appealing to both consumers and healthcare providers by enabling the market to grow at a CAGR of 8.00% from 2026 to 2032.

Epinephrine Autoinjector Market: Definition/ Overview

The epinephrine autoinjector is a life-saving medical device that treats severe allergic reactions such as anaphylaxis. It swiftly and effectively injects a measured quantity of epinephrine (also known as adrenaline) into the body to treat anaphylactic symptoms such as trouble breathing, swelling of the throat or face, low blood pressure, and rapid heartbeat. The gadget is intended to be simple to operate even by non-medical individuals in cases where immediate assistance is required.

The principal use of epinephrine autoinjectors is in emergency situations requiring immediate intervention to preserve lives. Individuals with known severe allergies or a history of anaphylaxis are frequently provided epinephrine autoinjectors and trained on how and when to use them. These devices are frequently kept on hand in schools, workplaces, and public areas where allergens may be present as part of emergency preparedness procedures. Prompt epinephrine injection can greatly improve outcomes by swiftly reversing the hazardous symptoms of anaphylaxis allowing critical time for emergency medical personnel to arrive.

The future of epinephrine autoinjectors looks promising as developments improve their effectiveness and accessibility in controlling severe allergic reactions like anaphylaxis. These devices which provide a precise dosage of epinephrine to reverse potentially fatal allergic reactions are evolving in several crucial areas. To begin, there is continuing research into enhancing the design and operation of autoinjectors so that they are easier to use in an emergency even by people who do not have medical experience.

Will the Increasing Prevalence of Food Allergies Drive the Epinephrine Autoinjector Market?

The increasing prevalence of food allergies around the world is driving the epinephrine autoinjector industry. For example, in the United States, Food Allergy Research & Education (FARE) says that 32 million people suffer from food allergies, a significant increase from prior years. Similarly, Australia's National Health and Medical Research Council (NHMRC) reports that 4-6% of children and 1-2% of adults have food allergies. These numbers show a consistent annual increase in food allergy cases.

Autoinjectors are essential for controlling severe allergic reactions because they allow patients to self-administer epinephrine rapidly and efficiently using a prefilled syringe. This is in contrast to traditional procedures which include constructing syringes or vials during an emergency. Autoinjectors have become indispensable for millions of people worldwide who suffer from food allergies due to their ease and simplicity giving a dependable means of quickly and successfully counteracting potentially fatal allergic responses.

Will High Prices of the Branded Devices Hamper the Epinephrine Autoinjector Market?

The high prices of branded epinephrine autoinjectors such as Pfizer's EpiPen provide a significant barrier to the whole market. These devices are critical for treating severe allergic responses (anaphylaxis) but their high costs frequently render them unavailable to many people who require them. This pricing issue also impacts healthcare facilities and schools which struggle to afford and keep enough supplies of these life-saving gadgets. For example, a 2021 survey revealed that a quarter of Chicago schools cited expensive prescription prices as a reason for not having epinephrine autoinjectors.

In response to these issues, there has been a gradual transition to more cost generic alternatives in recent years. These generics provide comparable efficacy but are less expensive intending to make epinephrine autoinjectors more accessible to a larger audience. Despite this tendency, the market for these gadgets will remain underdeveloped as long as branded solutions are priced excessively limiting availability and affordability. Efforts to overcome these cost restrictions could open up new business opportunities and ensure that more people and institutions have access to life-saving therapies for severe allergies.

Category-Wise Acumens

Will the Simplicity and Straightforward Administration Drive the Product Type Segment?

In the epinephrine autoinjector market, the dominance of single-dose and multiple-dose autoinjectors is frequently determined by a number of factors, the most important of which are patient demands, convenience of use, and regulatory considerations. Single-dose autoinjectors are commonly used in emergencies due to their simplicity and ease of administration. These devices are intended to provide a precise single dose of epinephrine which is critical for treating severe allergic reactions such as anaphylaxis quickly and effectively. Their user-friendly design and ease of deployment make them popular with patients, caregivers, and healthcare providers alike ensuring timely intervention in crucial situations.

Multiple-dose autoinjectors have the advantage of administering numerous doses of epinephrine without the need for reloading which can be useful in situations where repeat dosage is required or for patients who are at risk of developing multiple allergic responses. This feature offers increased protection and simplicity, perhaps decreasing the need for additional devices or refills over time. Regulatory concerns are also important since different locations may have different criteria and preferences for the kind of autoinjectors that are permitted for use. Finally, the decision between single-dose and multiple-dose autoinjectors is influenced by patient-specific needs, healthcare practitioner advice, and the regulatory guidelines that regulate medical devices in a given market.

Will the High Adoption of Autoinjector Devices Drive the End-User Segment?

Hospitals are the most common users of epinephrine autoinjectors because they are critical facilities for treating severe allergic reactions such as anaphylaxis. These medical facilities have epinephrine autoinjectors on hand in emergency departments, clinics, and patient wards. This ensures that patients who encounter severe allergic reactions which might occur unexpectedly and require prompt attention have quick access to life-saving medication. Hospitals also teach healthcare personnel and caregivers how to use epinephrine correctly which improves their ability to effectively manage cases of anaphylaxis.

Hospitals play an important role in the epinephrine autoinjector market because they treat severe allergic reactions like anaphylaxis. These medical facilities stock epinephrine autoinjectors in their emergency rooms, outpatient clinics, and patient wards. This ensures that patients who have abrupt, severe allergic reactions which can develop unexpectedly have fast access to life-saving medication. Furthermore, hospitals train healthcare personnel and caregivers on how to properly administer epinephrine reaffirming their critical role in effectively managing anaphylaxis.

Country/Region-wise Acumens

Will the Increasing Incidences of Anaphylaxis Drive the Market in North America?

North America is expected to lead the global epinephrine auto-injector market in the coming years. This is primarily due to easy availability to these products and the introduction of less expensive, generic competitors. The rising number of occurrences of anaphylaxis which are severe allergic responses caused by food, food additives, latex, and dust is also driving up demand for auto-injectors. People in North America have better access to anaphylactic therapies which increases the demand for these emergency devices.

Rising awareness of the significance of quick treatment for severe allergies contributes significantly to the market's growth. Health campaigns and education initiatives are educating more individuals about the dangers of anaphylaxis and the life-saving benefits of having an auto-injector. Furthermore, developments in healthcare infrastructure as well as the availability of health insurance plans that cover the cost of auto-injectors have made these devices more inexpensive and accessible to a greater audience. These combined factors contribute to North America's considerable share of the worldwide epinephrine auto-injector market over the forecast period.

Will Increasing Awareness about Dental Health Drive the Market in Asia Pacific Region?

The Asia Pacific region is expected to be the second-largest market for epinephrine autoinjectors accounting for more than of the market share in 2023. Countries such as China, India, and Japan are seeing an increase in acceptability of these devices owing primarily to increased awareness of severe food and drug allergies which can be fatal. This growing knowledge fuels demand for epinephrine autoinjectors which are critical for swiftly treating severe allergic reactions known as anaphylaxis. These countries are becoming significant markets for these lifesaving devices due to the increasing prevalence of allergies.

The Asia Pacific region is becoming an attractive investment destination for gadget manufacturers. This is attributable to a variety of factors including favorable legislation that make it simpler to bring medical equipment to market and rising healthcare spending which creates a more supportive climate for medical advances. Global businesses are lured to these advantageous conditions recognizing chances for growth and expansion. As a result, they can anticipate continuous investment and growth in the epinephrine autoinjector market in this region driven by the pressing need to manage the growing number of allergy patients as well as a favorable legislative and economic climate.

Competitive Landscape

The epinephrine autoinjector market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the epinephrine autoinjector market include:

Adamis Pharmaceuticals Corporation

ALK-Abello AS

Antares Pharma, Inc.

Bausch + Lomb UK Ltd- Emerade

Hospira, Inc.

Impax Laboratories, Inc.

Lincoln Medical

Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Latest Developments

In August 2022, Amphastar Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration had approved its New Drug Application for Epinephrine Single Dose Pre-Filled Syringe.

In February 2022, Sanofi bought Amunix providing access to Amunix Pro-XTEN, XPAT, and XPAC technology for next-generation Conditionally Activated Biologics.

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Epinephrine Autoinjector Market, By Product Type

Single-Dose Autoinjectors
Multiple-Dose Autoinjectors

5. Epinephrine Autoinjector Market, By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Retailers

6. Epinephrine Autoinjector Market, By End-user

Hospitals & Clinics
Homecare Settings
Schools & Educational Institutions

7. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

8. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

9. Competitive Landscape

Key Players
Market Share Analysis

10. Company Profiles

Mylan NPI LLC
Meridian Medical Technologies, Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Adrenalin Pharma LLC
ALLERGEN plc
Becton Dickinson and Company
Fresenius SE & Co. KGaA
Johnson & Johnson
Neogen Corporation

11. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

12. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年肾上腺素注射器市场（按产品类型、分销管道、最终用户和地区划分）

Epinephrine Autoinjector Market By Product Type, Distribution Channel, End-User, & Region For 2026-2032

肾上腺素注射器市场评估－2026-2032

食物过敏的增加会推动肾上腺素注射器市场的发展吗？

高品牌价格会阻碍肾上腺素注射器市场吗？

目录

第一章 引言

第二章执行摘要

第三章市场概述

第四章肾上腺素注射器市场（依产品类型）

第五章肾上腺素注射器市场（依通路）

第六章肾上腺素注射器市场（按最终用户）

第七章区域分析

第八章市场动态

第九章 竞争态势

第十章 公司简介

第十一章 市场展望与机会

第十二章 附录

Epinephrine Autoinjector Market Valuation - 2026-2032